Evolus, Inc. released its Q2 2023 earnings report, providing granular revenue breakdown data that illuminates Jeuveau's market position relative to Allergan Aesthetics' Botox and Galderma's Dysport. The filing offers practitioners a window into how the third-major toxin is tracking in the competitive landscape—critical for practices evaluating rebate programs and supply-chain partnerships.
Injectables
Evolus Q2 2023: Revenue Breakdown Signals Jeuveau Stabilization
Toxin maker's earnings reveal where Jeuveau stands against Botox and Dysport in competitive market.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Evolus's Q2 breakdown reveals where Jeuveau stands in the three-toxin market—critical data for rebate negotiations.
Jeuveau's performance reflects the reality of the modern toxin market: differentiation on onset speed and diffusion profile matters less than rebate depth and practitioner loyalty. Evolus has leaned into aggressive Aspire rebate positioning to gain shelf space, particularly among independent practices seeking alternatives to AbbVie's Alle ecosystem. The Q2 data helps practices benchmark their own Jeuveau utilization against market averages and assess whether the toxin's economics justify continued inventory commitment.
Source: original report ↗
Frequently asked questions
How does Jeuveau market share compare to Botox and Dysport?
Jeuveau holds the third position in the toxin market behind Botox (Allergan Aesthetics) and Dysport (Galderma). Evolus has gained traction among independent practices by positioning aggressive Aspire rebates as an alternative to AbbVie's Alle ecosystem, but remains the smaller player in overall market penetration.
What does Jeuveau's Q2 2023 earnings data tell practitioners about rebate strategy?
Evolus' Q2 results show that rebate depth and practitioner loyalty drive market share more than clinical differentiation. Practices evaluating Jeuveau should focus on comparing Aspire rebate programs against competitor offers rather than relying on onset speed or diffusion profile as primary decision factors.
Should I stock Jeuveau if I'm already using Botox or Dysport?
Q2 2023 data suggests Jeuveau makes economic sense primarily for independent practices seeking to reduce reliance on AbbVie's Alle ecosystem. Benchmark your own Jeuveau utilization against market averages to determine whether the rebate economics justify inventory commitment alongside existing toxin suppliers.
What is Jeuveau's competitive advantage in the toxin market?
Jeuveau's primary advantage is aggressive Aspire rebate positioning targeted at independent practices, not clinical differentiation. The toxin's onset speed and diffusion profile matter less than rebate depth when practitioners are deciding between the three major toxins.
How can practices use Evolus Q2 earnings to evaluate their toxin supply chain?
Use the Q2 revenue breakdown to assess Jeuveau's market traction and stability as a long-term supplier option. Compare Jeuveau's rebate programs and economics against Botox and Dysport offerings to determine whether diversifying your toxin portfolio aligns with your practice's profitability goals.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.